5 key facts about Egypt’s first biopharmaceuticals factory

Egypt is set to launch the Middle East’s first biopharmaceutical factory in early 2025, marking a major step in local healthcare production. With an investment of EGP 5 billion, the factory will manufacture advanced biopharmaceutical products, including monoclonal antibody drugs, which are crucial in treating diseases like cancer. This facility will not only make these medicines more affordable for the domestic market but also aims to export to over 80 countries, positioning Egypt as a regional leader in pharmaceutical manufacturing.

1. First in the Middle East
Egypt will be home to the region’s first biopharmaceutical factory, which is set to begin operations in early 2025.

2. EGP 5 Billion Investment
The facility represents a 100% locally funded investment, totaling EGP 5 billion.

3. Advanced Drug Manufacturing
The factory will produce cutting-edge biopharmaceuticals, including monoclonal antibody drugs used to treat cancer and other diseases.

4. Affordable Medicine
Locally produced biopharmaceuticals will be available at half the price of imports.

5. Export Potential
The factory plans to supply both the local market and export to over 80 countries.